US 8,410,060 B2 · Soluble tumor necrosis factor receptor treatment of medical disorders

Abstract

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.

Claims20

Dependent claims

A method for treating a patient having psoriatic arthritis comprising administering to the patient a therapeutically effective dose of TNFR:Fc.

Dependencies are inferred from the claim text.

Facts

Application

13/367,071Filed 6 Feb 2012 · division

Priority

19 Apr 1999

Published

US 2012/0135933 A131 May 2012

Granted

2 Apr 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 14/70578
Receptors; Cell surface antigens; Cell surface determinants: nGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 38/1793
Receptors; Cell surface antigens; Cell surface determinants: for cytokines; for lymphokines; for interferons
A61K 39/39533
Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum: against materials from animals

Family

Application60/130,074Us provisional application · filed 19 Apr 1999

Application60/134,320Us provisional application · filed 14 May 1999

Application60/143,959Us provisional application · filed 15 Jul 1999

Application60/148,234Us provisional application · filed 11 Aug 1999

Application09/373,828Parent of this continuation-in-part · filed 13 Aug 1999

Application60/164,676Us provisional application · filed 10 Nov 1999

Application60/184,864Us provisional application · filed 25 Feb 2000

Application09/602,351Parent of this division · filed 23 Jun 2000

Application10/853,479Parent of this division · filed 25 May 2004

Application12/394,962Parent of this continuation · filed 27 Feb 2009

Application13/021,545Parent of this division · filed 4 Feb 2011

US 2012/0135933 A1Pre-grant publication · published 31 May 2012

US 8,119,605 B2Parent of this division

US 7,915,225 B2Parent of this continuation

Application13/021,545Parent of this continuation

Application12/394,962Parent of this division

Application09/602,351Parent of this continuation-in-part

US 2004/0220103 A1Published application

US 2009/0163424 A1Published application

US 2011/0142832 A1Published application

US 8,410,060 B2This patent

From the US filing history. Foreign family members aren’t listed.